Ozempic personality is not a side effect — it is the point

A medical conference in Istanbul is hearing the argument that GLP-1 agonists could do for obesity what tobacco litigation did for smoking — move the moral weight off the individual and onto the industry that engineered the demand. In the popular health press, simultaneously, a different argument is taking shape, this one less editorial than testimonial: patients on these drugs are reporting a flattening of pleasure that extends past food, into sex and music and dancing and the basic interest in being around people. The two stories are filed in different sections of the same newspaper. They are not different stories.

They are the same story told from opposite ends, and the conclusion each one keeps offstage is the conclusion the other lives in. The case for shifting the blame for obesity from the fat individual to the food system concedes that what we called willpower was a description of an inflamed brain in a hostile environment. The case that the cure has a personality cost concedes that pleasure in food and pleasure in everything else are run from the same circuitry — and that turning down the first is the way you turn down the second. Bound together, the two essays announce something it would be more comfortable not to announce. The moral economy of selfhood the West has run on for two centuries — the one in which the will was the legible part of the person and the part that mattered — was built on a description of physiology nobody has the right to use anymore. Willpower is what gets surrendered first when the reward system is adjustable. We do not yet have a replacement frame, and the cultural conversation around Ozempic is the part of public life where that gap is showing.

This matters because the GLP-1 conversation is no longer a niche health story. The market has moved from people with severe diabetes to people who would once have joined a gym, to people who would once have dieted, to people who would once have simply been heavier than their parents and accepted it. The drugs are quietly becoming the answer to whether a person is going to choose, every day, to be the body she has or move to a body she prefers. The choice is a relief for many; it is also a verdict. It says the daily struggle was not, in the end, a fair test of anything. The drug tells you, finally, that if your wellness regime worked for you, you were not stronger than the person for whom it did not work; you were calmer at the dinner table. Your reward system was less inflamed than someone else’s. The dignity restored to the person who could not lose weight is the dignity revoked from your sense of yourself as the type who could.

The Hagenaars and Schmidt essay being presented at the European Congress on Obesity in Istanbul makes the social-medical version of the argument cleanly. The authors — Luc Hagenaars at Amsterdam UMC and Laura Schmidt at the University of California, San Francisco — note that GLP-1 agonists do not just reduce body weight; they reduce specifically the cravings for ultra-processed foods, the class of products that public-health researchers have spent two decades classifying as the proximate cause of the obesity transition. When a drug suppresses the demand for the very class of products public-health departments have already named as the central commercial pathology of the modern food environment, the obesity discourse runs out of room to keep blaming the fat person. The tobacco settlements did not require the moral rehabilitation of smokers; they required a public account of the industry that had aimed nicotine at them. The Ozempic era can be the same kind of moment for food, if the political will exists to use it that way. The drugs are the wedge; the policy is the lever.

In the same pages where this argument is being made, the Ozempic-personality reporting reads almost as if it were written to interrupt it. The Washington Post and the Boston Globe coverage, the patient interviews, the doctors quoted on what is happening to people who lose the appetite for everything alongside losing the appetite for food — these are stories about a cure with a charge. Patients describe themselves as flatter, less interested, less moved by what used to move them. The obesity researcher Daniel Drucker, who has spent decades on the biochemistry of this drug class, says simply that GLP-1s tone down the brain regions associated with pleasure. The clinical question is whether the drugs act directly on dopamine receptors, or whether they make satiety arrive earlier and the brain reads that arrival as a global signal to stop wanting things.

The detail matters clinically. It matters less to the cultural argument, which lands the moment the patient sits in a kitchen and notices that the music she used to love is now wallpaper, that the friends she used to seek out feel optional, that the partner she used to want has become a person she likes in the abstract. The shared circuitry was always going to do this, given the chance. The story we wrote on top of it was that food cravings were a failure of character. Once we treated those cravings with a drug, we got to see what else the same wiring was doing — running, it turns out, most of the things we had been calling appetite for life.

The moral economy this discovery embarrasses is older than most readers think. The twentieth-century health regime, with its calorie counting and its energy-in, energy-out balance, took a Calvinist account of the appetite and rendered it in physiological language for liberal democracies that needed a non-religious vocabulary for self-discipline. It worked, in the sense that millions of people structured their lives around it. It also produced, in its late phase, a moral hierarchy of bodies whose physical reality — the metabolic differences, the reward-system differences, the environmental differences — was hidden inside a vocabulary of will. The drug exposes the vocabulary. It does not exonerate every thin person of luck and it does not condemn every heavy person to medication. It just makes the previous account look like what it was, which was provisional.

The strongest version of the counter-argument is not the wellness influencer’s panic about pharmacology and it is not the conservative anxiety about modern bodies turning into modern non-bodies. It is the argument that the post-willpower frame is itself a category error. The position runs, in the hands of its most serious proponents, something like this. Willpower was never a description of an intact reward system; it was a description of a person’s relationship to a reward system, and that relationship was real, was malleable, and was sometimes the difference between a coherent life and an incoherent one. The Ozempic discourse confuses one thing — that some of the work we attributed to virtue was being done quietly by a calm hypothalamus — with another thing, which is that the work itself was illusory. The work was not illusory. The patient who, over years, built a practice of moderating her relationship to alcohol or food or work was not running a script the drug could now write for her in five seconds. She was building a self. The drug shortcuts the building. If we conclude from the Ozempic era that virtue was a fiction, we will lose the most useful frame human beings have for becoming people who can be lived with, including by themselves.

The steel-man gets one piece right and the rest wrong. It is right that practices of moderation are not nothing — that a woman who has spent ten years working out her relationship to her phone or her bottle or her dinner has done something the drug does not do, which is build a self around the work. The trouble is in the assumption that the older frame was naming the build correctly. It was not. The frame was naming the build as evidence of a character that was the cause of the work, when in many cases the character, the work, and the calm reward system were a single physiological-and-circumstantial accident the person was lucky enough to have. The Ozempic era does not erase the value of the practice; it removes the right to read it morally onto people who did not get the accident.

There is a quieter signal in the same conversation that the industry has already read. Restaurant operators have begun to model around customers ordering less alcohol, less dessert, less of the high-margin items the modern dinner menu was engineered to sell. The food economy that built itself around a particular shape of appetite is reading the new shape as a structural change rather than a fad. This is the part of the story the Hagenaars and Schmidt essay points to without naming. The cultural anxiety about Ozempic personality is, in part, the anxiety of a consumption pattern noticing that its consumer is no longer the consumer it took for granted. The drug is not simply a body intervention. It is a politics of demand.

What we do not have, in this moment, is the new theory of self the drug requires. The old theory was that the will was the agent and the body the field. The intermediate, post-Freudian theory was that the will and the drives were in conversation, with the conscious person trying to manage a basement she did not own. The new theory needs to begin with the recognition that the conscious person sits on top of a tunable reward system, and that the question of what we want — across food, sex, social presence, work, attention — is not separable from what we have decided, with or without consultation, to ask our reward system to want. This is not nihilism. It is the same problem the Stoics and the Buddhists worked on without the chemistry. The novelty is that the chemistry has now moved from the philosopher’s metaphor into the prescription pad.

The right reading is not that we should stop taking the drug, and not that we should stop reading the personality reports as significant. It is that the two reports together tell us what the drug actually does, which is to lift one set of involuntary inflammations off a person and, in the lifting, expose the rest of the involuntary inflammations the person was running on. The person we now have to think about, in policy and in moral life, is someone whose interior is no longer a private moral theatre but a chemistry that admits intervention from outside. That person is not a worse person than the old one. She is a different one. The job of the next decade of cultural argument is to give her a vocabulary that does not pretend she is the person of 1980.

The least helpful thing we can do is decide which of the two essays is the correct one. The blame-shift essay is correct. The personality essay is correct. Both are correct in the same way and for the same reason: they describe a person who was always going to be more reducible than the cultural account allowed. The drug did not invent this person. It revealed her, and asked her to live in public. The right of the food industry to be named as a co-author of the obesity transition is established by the same physiology that establishes the right of a patient to be told her flattened weekend feeling is not, as the previous frame would have said, evidence of a problem with her gratitude practice. It is evidence of the drug doing what the drug does. The work of the next argument is to decide what we want to want — and to admit that the question was always more interesting than the moralism with which we used to refuse to ask it.